Bulk - arcalyst 220MG VIL
Active Awarded Last action
- Contract number
- 36C26026F0076
- Awardee
-
Kiniksa Pharmaceuticals (Uk), LTD. UEI HBHWNLNMHSV5
- Awarding agency
-
Veterans Integrated Service Network 20
Veterans Health Administration, Department of Veterans Affairs
- Obligated
- $220,229
Award facts
- Contract value 100% obligated
- $220,229.15 Current and potential, with all options
- Completion date 85% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Dublin, OH 43017, USA
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Funding Only Action | $11,015 | |
| Original award | $209,215 |
About this award
The U.S. Department of Veterans Affairs, Veterans Integrated Service Network 20 (VISN 20) awarded a delivery order valued at $220,229.15 to Kiniksa Pharmaceuticals (UK), LTD. for the supply of bulk Arcalyst 220 mg vials, including a 2026 price increase. This firm fixed-price contract, issued December 15, 2025 with an ultimate completion date of December 14, 2026, operates under the General Services Administration's Pharmaceuticals and Drugs Federal Supply Schedule (FSS-61-IB) without a set-aside designation, indicating open competition procurement. The place of performance is Dublin, Ohio. Kinikska, a foreign-owned biopharmaceutical company headquartered in London, serves as the prime contractor with no identified subcontractors on this pharmaceutical supply agreement.
Arcalyst (rilonacept) is an injectable therapeutic agent indicated for treating chronic inflammatory disorders, including recurrent pericarditis and cryopyrin-associated periodic syndromes. This delivery order is issued under a larger $5.9 million Blanket Purchase Agreement between Kinikska and the VA National Acquisition Center (effective November 10, 2021 through November 9, 2026) and a $700,000 multiple-award Federal Supply Schedule contract with VISN 12 (effective November 1, 2021 through October 31, 2026). These indefinite delivery vehicles enable streamlined procurement of this specialized injectable across geographically dispersed VA medical facilities and support healthcare operations for eligible veteran populations. Kinikska has maintained a substantial portfolio of delivery orders under these vehicles, with collective obligations exceeding $1.7 million since October 2021.
Quick answers
Who was awarded contract 36C26026F0076?
36C26026F0076 was awarded to Kiniksa Pharmaceuticals (Uk), LTD. by Veterans Integrated Service Network 20 (Veterans Health Administration) on December 15, 2025.
How much is contract 36C26026F0076 worth?
The government has obligated $220,229 on 36C26026F0076.
Is contract 36C26026F0076 an order under another contract?
Yes. 36C26026F0076 is a delivery order under 36F79722D0002, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36C26026F0076 competed?
The extent of competition for 36C26026F0076 was full and open competition. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award